For this study, MediVas utilized its synthetic subunit vaccine which provides an alternative to traditional egg-based vaccines. The vaccine used the company's patented biodegradable polymer technology. This technology allows MediVas to produce a vaccine against any mutated influenza virus in as a short as five weeks.
“These data validate our novel technology and, in particular, our lead intranasal formulation, which showed a 100% survival rate, presents a meaningful advance in vaccine technology,” said Kenneth Carpenter CEO of MediVas.
MediVas also commented that the vaccine had shown high antibody response and good survival results across all formulations in the study.